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Background: The results of some clinical trials in percutaneous coronary interventions indicated more procedure related complications and 
worse clinical outcomes in women than men, but due to a lower representation of female patients this question still remains open. Our aim was to 
investigate the characteristics, early and late clinical outcome in female patient as compared to male when treated in a real life setting with a new 
generation drug eluting stent.
Methods: One thousand consecutive patients were treated with Nobori stent in 125 centres across Europe and Asia. Out of 1000 patients, 194 
(19.4%) were female. The primary endpoint is a composite of cardiac death, MI and target lesion revascularization (TLR) at 6 and 12 months, while 
secondary endpoints include stent thrombosis; death/MI; TLR/TVR up to five years. Data are entered in an electronic database with extensive on-line 
and on-site monitoring for all patients. All adverse clinical events are adjudicated by an independent committee.
Results: Compared to male patients, female patients were significantly older (68 ± 10 vs. 63 ± 11; p<0.0001), more frequently diabetics (36% vs 
27%; p=0.02) and hypertensive (73% vs 62%; p=0.01), had lower incidence of previous PCI/CABG (29% vs 39%; p=0.02). There were no statistically 
significant difference in any of assessed QCA parameters (lesion length was 15.3±9.8mm and 15.1±8.7mm; RVD 2.56 and 2.62mm; diameter 
stenosis 68±16% and 70±17%; acute gain 1.64±0.6 and 1.69±0.6 in female and male patients respectively). At 6 months follow-up hierarchical 
MACE rate was low in both groups (4.3% in female patient group vs. 3.1% in male patient group) the difference not statistically significant. The rate 
of stent thrombosis was higher in female patients (1.63% vs 0.52%: p=0.05)
Conclusions: Results of our study indicate that there are differences in the demographics and risk factors in female and male patient’s population. 
The frequency of adverse events at six months is relatively low in both populations, showing trend toward slightly higher rate in female patients. Long 
term follow-up is expected to further clarify similarity or differences in gender related treatment outcome.
